Drugs / LJPC-401
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03381833 Comparator | Nov 2017 → Dec 2019 | beta thalassemia | La Jolla Pharmaceutical Company | Terminated | No outcome recorded |
| Phase 2 | NCT03395704 Comparator | Nov 2017 → Oct 2019 | hereditary hemochromatosis | La Jolla Pharmaceutical Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LJPC-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03395704 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT03381833 ↗ |